Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,395 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Erratum to: Outcomes of trastuzumab therapy in HER2‑positive early breast cancer patients.
Yamshiro H, Iwata H, Masuda N, Yamamoto N, Nishimura R, Ohtani S, Sato N, Takahashi M, Kamio T, Yamazaki K, Saito T, Kato M, Lee T, Ohno S, Kuroi K, Takano T, Takada M, Yasuno S, Morita S, Toi M. Yamshiro H, et al. Among authors: yamamoto n. Int J Clin Oncol. 2015 Aug;20(4):723-4. doi: 10.1007/s10147-015-0814-7. Int J Clin Oncol. 2015. PMID: 25772578 No abstract available.
Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer.
Saeki T, Nomizu T, Toi M, Ito Y, Noguchi S, Kobayashi T, Asaga T, Minami H, Yamamoto N, Aogi K, Ikeda T, Ohashi Y, Sato W, Tsuruo T. Saeki T, et al. Among authors: yamamoto n. J Clin Oncol. 2007 Feb 1;25(4):411-7. doi: 10.1200/JCO.2006.08.1646. Epub 2006 Dec 18. J Clin Oncol. 2007. PMID: 17179098 Clinical Trial.
Randomized phase II study of three doses of oral TAS-108 in postmenopausal patients with metastatic breast cancer.
Inaji H, Iwata H, Nakayama T, Yamamoto N, Sato Y, Tokuda Y, Aogi K, Saji S, Watanabe K, Saito T, Yoshida M, Sato N, Saeki T, Takatsuka Y, Kuranami M, Yamashita H, Kikuchi A, Tabei T, Ikeda T, Noguchi S. Inaji H, et al. Among authors: yamamoto n. Cancer Sci. 2012 Sep;103(9):1708-13. doi: 10.1111/j.1349-7006.2012.02354.x. Epub 2012 Jul 16. Cancer Sci. 2012. PMID: 22676245 Free PMC article. Clinical Trial.
Final results of a safety and efficacy trial of preoperative sequential chemoradiation therapy for the nonsurgical treatment of early breast cancer: Japan Clinical Oncology Group Study JCOG0306.
Mukai H, Watanabe T, Mitsumori M, Tsuda H, Nakamura S, Masuda N, Yamamoto N, Shibata T, Sato A, Iwata H, Aogi K. Mukai H, et al. Among authors: yamamoto n. Oncology. 2013;85(6):336-41. doi: 10.1159/000355196. Epub 2013 Nov 12. Oncology. 2013. PMID: 24247597 Clinical Trial.
Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression.
Ando M, Yamauchi H, Aogi K, Shimizu S, Iwata H, Masuda N, Yamamoto N, Inoue K, Ohono S, Kuroi K, Hamano T, Sukigara T, Fujiwara Y. Ando M, et al. Among authors: yamamoto n. Breast Cancer Res Treat. 2014 Jun;145(2):401-9. doi: 10.1007/s10549-014-2947-1. Epub 2014 Apr 12. Breast Cancer Res Treat. 2014. PMID: 24728578 Clinical Trial.
Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients.
Yamshiro H, Iwata H, Masuda N, Yamamoto N, Nishimura R, Ohtani S, Sato N, Takahashi M, Kamio T, Yamazaki K, Saito T, Kato M, Lee T, Ohno S, Kuroi K, Takano T, Takada M, Yasuno S, Morita S, Toi M. Yamshiro H, et al. Among authors: yamamoto n. Int J Clin Oncol. 2015 Aug;20(4):709-22. doi: 10.1007/s10147-015-0785-8. Epub 2015 Feb 10. Int J Clin Oncol. 2015. PMID: 25666483
6,395 results